Literature DB >> 1301400

An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol.

S Y Jiang1, D M Wolf, J M Yingling, C Chang, V C Jordan.   

Abstract

The antiestrogen tamoxifen has been successfully used to control estrogen receptor (ER) and progesterone receptor positive breast cancer. However, the development of antiestrogen resistance is frequently observed in patients following long term treatment. We have studied the development of antiestrogen resistance in vitro and established an antiestrogen resistant variant of MCF-7 cells (clone 5C) after long term culture in estrogen free medium. The growth of clone 5C cells was not altered by either estradiol-17 beta or the antiestrogens 4-hydroxytamoxifen and ICI 164,384. Estrogen-stimulated progesterone receptor and reporter gene expression were markedly reduced in 5C cells compared to wild type MCF-7 cells. Only minor alteration in the levels of ER and no alteration in the affinity of ER for ligand were found in 5C cells. No mutation of ER cDNA in 5C cells was detected by polymerase chain reaction and DNA sequencing. This study demonstrates that change(s) in ER-mediated gene expression rather than the amino acid sequence of the ER itself may be associated with the development of at least one form of antiestrogen resistance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1301400     DOI: 10.1016/0303-7207(92)90104-e

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  58 in total

1.  Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.

Authors:  Surojeet Sengupta; Michael C Biarnes; Robert Clarke; V Craig Jordan
Journal:  Breast Cancer Res Treat       Date:  2015-02-27       Impact factor: 4.872

2.  Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1.

Authors:  Prashant Rajbhandari; Greg Finn; Natalia M Solodin; Kiran K Singarapu; Sarata C Sahu; John L Markley; Kelley J Kadunc; Stephanie J Ellison-Zelski; Anastasia Kariagina; Sandra Z Haslam; Kun Ping Lu; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

3.  Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time.

Authors:  Eric A Ariazi; Heather E Cunliffe; Joan S Lewis-Wambi; Michael J Slifker; Amanda L Willis; Pilar Ramos; Coya Tapia; Helen R Kim; Smitha Yerrum; Catherine G N Sharma; Emmanuelle Nicolas; Yoganand Balagurunathan; Eric A Ross; V Craig Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-19       Impact factor: 11.205

4.  The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.

Authors:  Joan S Lewis-Wambi; Helen Kim; Ramona Curpan; Ronald Grigg; Mohammed A Sarker; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2011-07-07       Impact factor: 4.436

Review 5.  Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.

Authors:  V Craig Jordan; Joan Lewis-Wambi; Helen Kim; Heather Cunliffe; Eric Ariazi; Catherine G N Sharma; Heather A Shupp; Ramona Swaby
Journal:  Breast       Date:  2007-08-24       Impact factor: 4.380

6.  The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.

Authors:  Eric A Ariazi; Eugen Brailoiu; Smitha Yerrum; Heather A Shupp; Michael J Slifker; Heather E Cunliffe; Michael A Black; Anne L Donato; Jeffrey B Arterburn; Tudor I Oprea; Eric R Prossnitz; Nae J Dun; V Craig Jordan
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

7.  Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.

Authors:  Ping Fan; V Craig Jordan
Journal:  Steroids       Date:  2014-06-12       Impact factor: 2.668

8.  Dynamic, large-scale profiling of transcription factor activity from live cells in 3D culture.

Authors:  Michael S Weiss; Beatriz Peñalver Bernabé; Abigail D Bellis; Linda J Broadbelt; Jacqueline S Jeruss; Lonnie D Shea
Journal:  PLoS One       Date:  2010-11-17       Impact factor: 3.240

9.  Bioluminescence imaging for assessment and normalization in transfected cell arrays.

Authors:  Angela K Pannier; Eric A Ariazi; Abigail D Bellis; Zain Bengali; V Craig Jordan; Lonnie D Shea
Journal:  Biotechnol Bioeng       Date:  2007-10-01       Impact factor: 4.530

10.  Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins.

Authors:  Remedios Castelló-Cros; David R Khan; Jeffrey Simons; Matthildi Valianou; Edna Cukierman
Journal:  BMC Cancer       Date:  2009-03-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.